RaQualia Pharma Inc. (TYO:4579)
Japan flag Japan · Delayed Price · Currency is JPY
899.00
+12.00 (1.35%)
Mar 6, 2026, 3:30 PM JST

RaQualia Pharma Income Statement

Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,9803,1071,9012,9182,776
Revenue Growth (YoY)
28.10%63.44%-34.85%5.12%150.77%
Cost of Revenue
711.95625245231321
Gross Profit
3,2682,4821,6562,6872,455
Selling, General & Admin
1,184782615566615
Research & Development
1,6001,7031,3721,2481,127
Amortization of Goodwill & Intangibles
-203---
Operating Expenses
2,7842,6951,9931,8201,747
Operating Income
483.72-213-337867708
Interest Expense
-59.06-42-7-6-1
Interest & Investment Income
26.86891322
Currency Exchange Gain (Loss)
-40.78385243145
Other Non Operating Income (Expenses)
27.2-13011-17-1
EBT Excluding Unusual Items
437.95-339-272900873
Gain (Loss) on Sale of Investments
-4--3516
Asset Writedown
--23-223-10
Other Unusual Items
----18-
Pretax Income
437.95-358-294850879
Income Tax Expense
164.8313729127124
Net Income
273.12-495-323723755
Net Income to Common
273.12-495-323723755
Net Income Growth
----4.24%-
Shares Outstanding (Basic)
2422222121
Shares Outstanding (Diluted)
2422222121
Shares Change (YoY)
11.14%0.16%2.97%0.05%0.10%
EPS (Basic)
11.53-22.87-14.9534.4836.03
EPS (Diluted)
11.36-22.87-14.9534.4736.03
EPS Growth
----4.34%-
Free Cash Flow
-421.7884-9231,449274
Free Cash Flow Per Share
-17.543.88-42.7269.0613.06
Gross Margin
82.11%79.88%87.11%92.08%88.44%
Operating Margin
12.15%-6.86%-17.73%29.71%25.50%
Profit Margin
6.86%-15.93%-16.99%24.78%27.20%
Free Cash Flow Margin
-10.60%2.70%-48.55%49.66%9.87%
EBITDA
971.88188-1621,014849
EBITDA Margin
24.42%6.05%-8.52%34.75%30.58%
D&A For EBITDA
488.16401175147141
EBIT
483.72-213-337867708
EBIT Margin
12.15%-6.86%-17.73%29.71%25.50%
Effective Tax Rate
37.64%--14.94%14.11%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.